ClinicalTrials.gg
CompletedNCT02845479POISEUpdated Sep 20, 2024

The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I

A Phase 3 interventional study of Integrative Care in Lung Neoplasms, Esophageal Neoplasms and Stomach Neoplasms, sponsored by The Canadian College of Naturopathic Medicine. Completed at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-20.

Sponsored by The Canadian College of Naturopathic Medicine · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 383 studies in Lung Neoplasms with a site in Canada — 66 open to participants now, 99 under way, 26 of them phase 3. Lung Neoplasms · Canada.

Enrollment
268th of 315
22 · median 100
Started
2018
with 15 others
Phase 3
77 of 383
13 open now
Registered
219th of 383
by date

Among the 383 studies in Lung Neoplasms with a site in Canada, this one is the 268th largest by enrollment of the 315 interventional ones that give a count, is one of 16 that started in 2018, is one of 77 in phase 3, and was the 219th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

66 of the 383 studies in Lung Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 383 studies in Lung Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

Stage I of the Thoracic-POISE study will pilot-test a broad-based, multi-agent integrative care intervention delivered by naturopathic doctors in conjunction with standard surgical and oncologic care of people with thoracic cancer.

Read the detailed description

Despite enormous advances in thoracic surgery and oncology, two critical issues concern patients undergoing curative-intent surgery for lung, gastric and esophageal cancer: first, a majority (\~60%) of patients experience minor and major adverse events occurring during and in the days following surgery; second, patients worry about the significant risk of cancer recurrence and mortality months to years after surgery. These issues, combined with side effects of chemotherapy and radiation, have detrimental effects on health-related quality of life (HRQoL). On a deeper level, there is the problem of an ongoing failure to integrate and evaluate the best of what complementary medicine has to offer surgical oncology care.

The Thoracic-POISE Project has the overarching goal of improving care for thoracic cancer patients by impacting HRQoL, reducing surgical adverse events, prolonging overall survival and pioneering integrative care delivery. This multi-stage project aims to design, pilot-test and evaluate a broad-based, multi-agent, evidence-based integrative care program to be delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care. It is hypothesized that this integrative care program will improve HRQoL as well as reduce surgical adverse events and improve cancer survival. Stage I of the project will pilot-test the intervention and outcomes collection in a single-arm, feasibility study.

03

Conditions studied

  • Lung Neoplasms
  • Esophageal Neoplasms
  • Stomach Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults eligible and scheduled for major thoracic surgery for lung, gastric or esophageal cancer
  • Candidate for complete resection
  • Willingness to include an integrative component to their care
  • Availability for follow-up visits over the course of one year
  • Willingness to be interviewed regarding their experience of care
  • Ability to answer self- and interviewer- administered questions in English or French
  • Understand and sign a written form in English or French

Exclusion criteria

Exclusion Criteria:

  • Small cell, carcinoid, or gastrointestinal stromal (GIST) tumours
  • History of cancer in the last 3 years
  • Already seeing a ND or involved in an integrative program of care in the last 3 months that includes complementary medicine
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Integrative Care Intervention

    Broad-based, multi-agent integrative care program delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care.

    Other: Integrative Care

Interventions

  • OtherIntegrative Care

    Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).

06

What researchers measure

Primary outcomes

  1. Feasibility of study protocol

    Percentage of participants who complete all assessments and integrative care appointments

    Time frame: Enrollment - 1 year post surgery

Secondary outcomes

  1. Compliance: supplemental intervention

    Count of missed doses assessed by patient diary.

    Time frame: Enrollment - 1 year post surgery

  2. Compliance: nutritional intervention

    Mediterranean diet score calculated by food frequency questionnaire administered at enrollment and 1 year post surgery

    Time frame: Enrollment - 1 year post surgery

  3. Compliance: physical intervention

    Extent of adherence to physical activity recommendations assessed using a patient diary.

    Time frame: Enrollment - 1 year post surgery

  4. Compliance: mental/emotional domain

    Number of days audio-recordings were used assessed by patient diary.

    Time frame: Enrollment - 1 year post surgery

  5. Communication between practitioners

    Number of communications (phone, consult note, etc.) between integrative and standard care practitioners per participant

    Time frame: Enrollment - 1 year post surgery

  6. Qualitative experience of care and study protocol

    Semi-structured interviews with thematic analysis

    Time frame: Enrollment - 1 year post surgery

  7. Feasibility of recruitment

    Percentage of participants recruited out of potentially eligible patients invited.

    Time frame: Enrollment

Other outcomes

  1. Adverse events

    Collection of adverse events related to surgery, adjuvant therapy, and the interventions

    Time frame: Enrollment - 1 year post surgery

  2. Health Related Quality of Life

    Functional Assessment of Cancer Therapy-General Score

    Time frame: Enrollment - 1 year post surgery

  3. Cancer-related symptoms

    Edmonton Symptom Assessment Scale

    Time frame: Enrollment - 1 year post surgery

  4. Anxiety and Depression

    Hospital Anxiety and Depression Scale

    Time frame: Enrollment - 1 year post surgery

  5. Fatigue

    Multidimensional Fatigue Inventory

    Time frame: Enrollment - 1 year post surgery

  6. Functional exercise capacity

    6 minute walk test

    Time frame: Enrollment - 1 year post surgery

  7. Inflammation: Multi-analyte cytokine array.

    Plasma concentrations of a panel of cytokines (IL2, IL10, TGF-beta, TNF-alpha, IFN-alpha, and IFN-gamma) will be measured in blood samples collected 4 weeks before surgery, 2-3 days before surgery, on post-operative day (POD) 1, POD 5 (+/-2), 3-4 weeks, 6 months and 1 year post-surgery

    Time frame: Enrollment - 1 year post surgery

  8. Natural kill cell activation

    NK cell activity will be measured by NKVue™ in blood samples collected 4 weeks before surgery, 2-3 days before surgery, on post-operative day (POD) 1, POD 5 (+/-2), 3-4 weeks, 6 months and 1 year post-surgery

    Time frame: Enrollment - 1 year post surgery

07

Study locations

2 sites
  • Ottawa General Hospital
    Ottawa, Ontario K1Y 1J7, Canada
  • Ottawa Integrative Cancer Centre
    Ottawa, Ontario K1Y2E5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Dec 2020, 23 months.

Of 65 non-industry phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 99. This study's 23 months is below that.

Counting every sponsor, half of 127 studies reached it within 43 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2016
First posted
Jul 27, 2016
StartActual
Dec 7, 2018
Primary completionActual
Dec 1, 2020
CompletionActual
Dec 7, 2020
Last update
Sep 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02845479
Lead sponsor
The Canadian College of Naturopathic Medicine
Collaborators
Ottawa Hospital Research Institute, Lotte & John Hecht Memorial Foundation
Responsible party
Sponsor
First posted
Jul 27, 2016
Start date
Dec 7, 2018
Primary completion
Dec 1, 2020
Completion
Dec 7, 2020
Last update
Sep 20, 2024

Study contacts

Dugald MR Seely, ND, MSc
principal investigator · Canadian College of Naturopathic Medicine
Andrew JE Seely, MD, PhD
principal investigator · Ottawa Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion